Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Measurable M-spike before ASCT associated with shorter survival in AL Amyloidosis

Morie Gertz • 30 Nov 2020
ASH 2020
Amyloidosis Rare Diseases

In this video, Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses research showing that the presence of a measurable monoclonal spike (M-spike) before autologous stem cell transplantation (ASCT) is associated with shorter survival in patients with light chain (AL) amyloidosis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Morie Gertz

1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals